AbClon Inc is a Korea-based company principally engaged in the development, manufacture and distribution of antibody drug. The Company developed a bio synergy antibody, a therapeutic antibody for a new mechanism that is different from conventional therapeutic agents, and is based on the YPLUS and AffiMab platforms. The company's products include AC101, AC103, AC104, AC106, AC203, AM201, AM101, AM102 and AM103. The Company distributes its products within domestic market and to overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
21/26/21	₩27,550.00	-8.47%	1,93,221
20/26/20	₩30,100.00	+1.18%	2,61,766
19/26/19	₩29,750.00	+1.71%	2,40,155
18/26/18	₩29,250.00	-9.58%	2,27,148
14/26/14	₩32,350.00	+4.35%	2,77,205

End-of-day quote Korea S.E.

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. 21/08/2026			5-day change	1st Jan Change
27,550.00 ^KRW	-8.47%		-14.84%	-35.18%

08/06	Alligator partner Henlius doses first patients in HLX22 study	FW
22/05	Alligator Bioscience comments on Henlius update for HLX22	FW

Market Cap	55TCr 40Cr 34Cr 32Cr 29Cr 55Cr 3.79TCr 55Cr 375.58Cr 146.47Cr 1.91TCr 148.93Cr 145.69Cr 6.31TCr	P/E 2024	-14.5x	P/E 2025	-43.5x
Enterprise Value	51TCr 37Cr 32Cr 30Cr 27Cr 51Cr 3.53TCr 52Cr 349.67Cr 136.36Cr 1.77TCr 138.65Cr 135.64Cr 5.87TCr	EV / Sales 2024	103x	EV / Sales 2025	164x
Free-Float	80.08%	Yield 2024 *	-	Yield 2025	-

08/06	Alligator partner Henlius doses first patients in HLX22 study	FW
22/05	Alligator Bioscience comments on Henlius update for HLX22	FW
23/04	Alligator partner Henlius presents preclinical data for HLX49	FW
23/04	Alligator Bioscience Announces Preclinical Data Presentation of Hlx49 Antibody?Drug Conjugate	CI
07/04	Abclon wins 396 million won order	RE
09/03	AbClon wins 778 million won order	RE
02/03	Alligator Bioscience: First Patient Dosed in Phase 2/3 Study with HLX22 in China	FW
01/25/01	AbClon Inc. announced that it expects to receive KRW 35.999952065 billion in funding from Paratus Investment Inc., Dongyu Investment Co., Ltd, Winvest Venture Capital and other investors.	CI
27/25/27	Abclon wins 309 million won order	RE
20/25/20	Abclon Wins 354 Million Won Order	RE
19/25/19	AbClon Inc To Issue 1.4 Million Common Shares	RE
19/25/19	AbClon Inc. announced that it has received KRW 12.2122 billion in funding from Chong Kun Dang Pharmaceutical Corp.	CI
15/25/15	Abclon Wins 307 Million Won Order	RE

08/06	Alligator Bioscience comments on Henlius update on global phase 3 trial with HLX22	AQ
22/05	Alligator Bioscience comments on Henlius update on long-term follow-up data for HLX22	AQ
23/04	Alligator Bioscience comments on Henlius presentation of HLX49 preclinical data at AACR 2026	AQ
02/03	Alligator Bioscience comments on Henlius dosing first patient in Phase 2/3 breast cancer study of HLX22	AQ
04/24/04	Alligator Announces First Patient Dosed in Shanghai Henlius Biotech, Inc. Phase 3 Clinical Trial	AQ

AbClon Inc. Share Price

Stocks

A174900

KR7174900001

Pharmaceuticals

Valuation: AbClon Inc.

Chart: AbClon Inc.

Latest news : AbClon Inc.

Press Releases: AbClon Inc.

Quotes and Performance

Course Extremes

Managers and Directors: AbClon Inc.

Biopharmaceuticals

Financials

Company Profile

Quotes

1 day	-8.47%
1 week	-14.84%
Current month	+39.85%
1 month	+38.65%
3 months	-30.60%
6 months	-49.26%
Current year	-35.18%

1 week	26,500	32,900
1 month	16,250	35,700
Current year	16,250	95,800
1 year	9,870	95,800
3 years	6,810	95,800
5 years	6,810	95,800
10 years	6,810	95,800

Manager	Title	Age	Since
Jong-Seo Lee CEO	Chief Executive Officer	63	25/06/2010
Doo-Hun Kim DFI	Director of Finance/CFO	59	28/03/2024
Jong-Hoon Kim CTO	Chief Tech/Sci/R&D Officer	57	29/03/2023

Director	Title	Age	Since
Jong-Seo Lee BRD	Director/Board Member	63	-
Jung-Ho Kim BRD	Director/Board Member	62	29/03/2021
Jong-Hoon Kim BRD	Director/Board Member	57	29/03/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABCLON INC.	-8.47%	-14.84%	+178.56%	+76.04%	40Cr
REGENERON PHARMACEUTICALS, INC.	+0.90%	+3.80%	+39.43%	-1.22%	8.33TCr
CSL LIMITED	-1.69%	+23.30%	-25.53%	-36.93%	5.78TCr
MODERNA, INC.	+8.86%	+129.20%	+453.51%	+30.65%	5.79TCr
SAMSUNG BIOLOGICS CO.,LTD.	-1.46%	+0.19%	-0.81%	+29.66%	5.17TCr
UCB	+1.74%	+4.43%	+11.41%	+172.02%	4.93TCr
BIOGEN INC.	+1.13%	+3.31%	+55.82%	-18.22%	3.2TCr
INCYTE CORPORATION	+0.46%	+6.37%	+47.71%	+96.99%	2.59TCr
INNOVENT BIOLOGICS, INC.	+1.19%	+9.17%	+3.12%	+228.73%	2.27TCr
ALTEOGEN INC.	-5.74%	+1.91%	+2.59%	+825.47%	1.61TCr
Average	-1.16%	+16.68%	+76.58%	+140.32%	3.97TCr
Weighted average by Cap.	-0.04%	+24.87%	+80.07%	+75.51%

	2024	2025
Net sales	233.98Cr 16.88L 14.46L 13.53L 12.39L 23.25L 16Cr 23.55L 1.6Cr 62.35L 8.11Cr 63.39L 62.02L 27Cr	471.41Cr 34.01L 29.14L 27.26L 24.96L 46.84L 33Cr 47.45L 3.22Cr 1.26Cr 16Cr 1.28Cr 1.25Cr 54Cr
Net income	-1.63TCr -1.18Cr -1.01Cr -94.28L -86.3L -1.62Cr -112.54Cr -1.64Cr -11Cr -4.34Cr -57Cr -4.42Cr -4.32Cr -187Cr	-1.79TCr -1.29Cr -1.11Cr -1.04Cr -94.8L -1.78Cr -123.63Cr -1.8Cr -12Cr -4.77Cr -62Cr -4.85Cr -4.75Cr -205.41Cr
Net Debt	-461.19Cr -33.28L -28.51L -26.67L -24.42L -45.82L -32Cr -46.43L -3.15Cr -1.23Cr -16Cr -1.25Cr -1.22Cr -53Cr	-3.79TCr -2.74Cr -2.34Cr -2.19Cr -2.01Cr -3.77Cr -261.83Cr -3.82Cr -26Cr -10Cr -131.53Cr -10Cr -10Cr -435.04Cr